Investigators are evaluating the safety and efficacy of the investigational antibody-drug conjugate vic-trastuzumab duocarmazine in patients with HER2-expressing recurrent, advanced, or metastatic endometrial cancer in the phase 2 SYD985.003 trial.
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent…
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor…
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
